Eric R Lechman
Overview
Explore the profile of Eric R Lechman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Araujo J, Wagenblast E, Voisin V, McLeod J, Gan O, Bansal S, et al.
Blood
. 2025 Jan;
PMID: 39841016
Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and relapse, but therapies tailored towards eradicating LSCs without harming normal hematopoietic stem cells (HSCs) are lacking. FLT3 is considered...
2.
Boila L, Ghosh S, Bandyopadhyay S, Jin L, Murison A, Zeng A, et al.
Leukemia
. 2023 Jan;
37(4):751-764.
PMID: 36720973
Acute myeloid leukemia (AML) is a heterogeneous, aggressive malignancy with dismal prognosis and with limited availability of targeted therapies. Epigenetic deregulation contributes to AML pathogenesis. KDM6 proteins are histone-3-lysine-27-demethylases that...
3.
Krivdova G, Voisin V, Schoof E, Marhon S, Murison A, McLeod J, et al.
Cell Rep
. 2022 Mar;
38(10):110481.
PMID: 35263585
Gene expression profiling and proteome analysis of normal and malignant hematopoietic stem cells (HSCs) point to shared core stemness properties. However, discordance between mRNA and protein signatures highlights an important...
4.
Subedi A, Liu Q, Ayyathan D, Sharon D, Cathelin S, Hosseini M, et al.
Cell Stem Cell
. 2021 Jul;
28(10):1851-1867.e8.
PMID: 34293334
Current treatments for acute myeloid leukemia (AML) are often ineffective in eliminating leukemic stem cells (LSCs), which perpetuate the disease. Here, we performed a metabolic drug screen to identify LSC-specific...
5.
Wagenblast E, Araujo J, Gan O, Cutting S, Murison A, Krivdova G, et al.
Science
. 2021 Jul;
373(6551).
PMID: 34244384
Children with Down syndrome have a 150-fold increased risk of developing myeloid leukemia, but the mechanism of predisposition is unclear. Because Down syndrome leukemogenesis initiates during fetal development, we characterized...
6.
Wagenblast E, Azkanaz M, Smith S, Shakib L, McLeod J, Krivdova G, et al.
Nat Commun
. 2019 Oct;
10(1):4730.
PMID: 31628330
In the human hematopoietic system, rare self-renewing multipotent long-term hematopoietic stem cells (LT-HSCs) are responsible for the lifelong production of mature blood cells and are the rational target for clinical...
7.
Aqaqe N, Yassin M, Yassin A, Ershaid N, Katz-Even C, Zipin-Roitman A, et al.
Cancer Res
. 2019 Jun;
79(15):3862-3876.
PMID: 31175119
Acute leukemia is a rapidly progressing blood cancer with low survival rates. Unfavorable prognosis is attributed to insufficiently characterized subpopulations of leukemia stem cells (LSC) that drive chemoresistance and leukemia...
8.
Kaufmann K, Garcia-Prat L, Liu Q, Ng S, Takayanagi S, Mitchell A, et al.
Blood
. 2019 Feb;
133(20):2198-2211.
PMID: 30796022
There is a growing body of evidence that the molecular properties of leukemia stem cells (LSCs) are associated with clinical outcomes in acute myeloid leukemia (AML), and LSCs have been...
9.
Yassin M, Aqaqe N, Yassin A, van Galen P, Kugler E, Bernstein B, et al.
Leukemia
. 2019 Feb;
33(8):2061-2077.
PMID: 30705411
Acute leukemia is an aggressive blood malignancy with low survival rates. A high expression of stem-like programs in leukemias predicts poor prognosis and is assumed to act in an aberrant...
10.
Schoof E, Lechman E, Dick J
Data Brief
. 2016 Sep;
9:57-61.
PMID: 27656662
A deep proteomics analysis was conducted on a primary acute myeloid leukemia culture system to identify potential protein targets regulated by miR-126. Leukemia cells were transduced either with an empty...